Mylan Wants Out Of Investor Suit Over FDA Inspections

Law360 (January 20, 2021, 5:37 PM EST) -- Pharmaceutical company Mylan NV told a Pennsylvania federal judge Tuesday he should toss a proposed class action alleging securities fraud because the company made "unvarnished disclosures" about its quality assurance and compliance with the U.S. Food and Drug Administration's regulations.

The drug giant said in its motion to dismiss that while the suit alleges securities fraud, the details of the complaint instead focus on the company's compliance with FDA regulations and doesn't show specifically how the company and its executives allegedly duped shareholders.

"It is easy to lose sight of the fact that this is an action asserting securities fraud claims,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!